1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22067
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNaka, K. K.en
dc.contributor.authorPapathanassiou, K.en
dc.contributor.authorBechlioulis, A.en
dc.contributor.authorPappas, K.en
dc.contributor.authorKazakos, N.en
dc.contributor.authorKanioglou, C.en
dc.contributor.authorKostoula, A.en
dc.contributor.authorVezyraki, P.en
dc.contributor.authorMakriyiannis, D.en
dc.contributor.authorTsatsoulis, A.en
dc.contributor.authorMichalis, L. K.en
dc.date.accessioned2015-11-24T19:20:51Z-
dc.date.available2015-11-24T19:20:51Z-
dc.identifier.issn1752-8984-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22067-
dc.rightsDefault Licence-
dc.titleEffects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureasen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1177/1479164111424515-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/22049096-
heal.identifier.secondaryhttp://dvr.sagepub.com/content/9/1/52.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2012-
heal.abstractPioglitazone and metformin are insulin sensitisers used for the treatment of T2DM. The effects of pioglitazone and metformin on endothelial function, assessed by FMD, in T2DM patients treated with sulfonylureas were compared. Patients were randomised to receive pioglitazone (n = 15) 30 mg once daily or metformin (n = 16) 850 mg twice daily for six months. Pioglitazone significantly decreased fasting insulin, HbA(1C) and HOMA-IR (p < 0.05 for all) and increased FMD (p = 0.002). Metformin induced a significant decrease in HbA(1C) (p = 0.02) and only a trend for increase in FMD (p = 0.08). The greater improvement in FMD with pioglitazone, compared with metformin, did not reach significance (p = 0.11). Treatment-induced changes in FMD were not associated with the effects of the two insulin sensitisers on glycaemic control or insulin resistance. The beneficial effects of pioglitazone and metformin on endothelial function in T2DM patients did not differ greatly. Larger studies are needed to explore whether a potentially greater benefit with pioglitazone may exist.en
heal.journalNameDiab Vasc Dis Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Naka-2012-Effects of pioglitaz.pdf342.96 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons